(NASDAQ: TBPH) Theravance Biopharma's forecast annual revenue growth rate of -3.2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.91%.
Theravance Biopharma's revenue in 2026 is $104,311,000.On average, 8 Wall Street analysts forecast TBPH's revenue for 2026 to be $6,188,715,477, with the lowest TBPH revenue forecast at $3,938,660,516, and the highest TBPH revenue forecast at $10,029,664,898. On average, 8 Wall Street analysts forecast TBPH's revenue for 2027 to be $5,135,803,146, with the lowest TBPH revenue forecast at $4,009,893,046, and the highest TBPH revenue forecast at $7,959,144,988.
In 2028, TBPH is forecast to generate $4,912,396,747 in revenue, with the lowest revenue forecast at $4,135,536,431 and the highest revenue forecast at $5,578,150,930.